Galectin Therapeutics Inc. (GALT) Financial Statements (2026 and earlier)
Company Profile
| Business Address |
4960 PEACHTREE INDUSTRIAL BOULEVARD NORCROSS, GA 30071 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 15,120,000 | 25,660,000 | 18,592,000 | 39,648,000 | 27,142,000 | 47,480,000 | |||
| Cash and cash equivalent | 15,120,000 | 25,660,000 | 18,592,000 | 39,648,000 | 27,142,000 | 47,480,000 | |||
| Other undisclosed current assets | 2,132,000 | 2,050,000 | 1,960,000 | 2,172,000 | 2,323,000 | 729,000 | |||
| Total current assets: | 17,252,000 | 27,710,000 | 20,552,000 | 41,820,000 | 29,465,000 | 48,209,000 | |||
| Noncurrent Assets | |||||||||
| Other noncurrent assets | 243,000 | 490,000 | 733,000 | 7,000 | 135,000 | 258,000 | |||
| Total noncurrent assets: | 243,000 | 490,000 | 733,000 | 7,000 | 135,000 | 258,000 | |||
| TOTAL ASSETS: | 17,495,000 | 28,200,000 | 21,285,000 | 41,827,000 | 29,600,000 | 48,467,000 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 13,860,000 | 15,613,000 | 12,948,000 | 9,033,000 | 1,357,000 | 1,727,000 | |||
| Interest and dividends payable | ✕ | ✕ | ✕ | ✕ | 65,000 | 65,000 | 66,000 | ||
| Accounts payable | 5,656,000 | 6,431,000 | 3,890,000 | 1,805,000 | 1,292,000 | 1,661,000 | |||
| Accrued liabilities | 8,204,000 | 9,182,000 | 9,058,000 | 7,163,000 | |||||
| Derivative instruments and hedges, liabilities | 369,000 | ||||||||
| Other undisclosed current liabilities | 21,180,000 | 63,000 | 64,000 | 4,042,000 | 1,093,000 | ||||
| Total current liabilities: | 35,409,000 | 15,676,000 | 13,012,000 | 9,033,000 | 5,399,000 | 2,820,000 | |||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt | 47,000 | 1,044,000 | 705,000 | 1,130,000 | 8,000 | 52,000 | |||
| Other liabilities | 20,000 | 66,000 | 8,000 | 52,000 | |||||
| Operating lease, liability | 20,000 | 66,000 | |||||||
| Derivative instruments and hedges, liabilities | 47,000 | 1,004,000 | 573,000 | 1,130,000 | |||||
| Other undisclosed noncurrent liabilities | 85,109,000 | 71,721,000 | 39,762,000 | 29,048,000 | |||||
| Total noncurrent liabilities: | 85,156,000 | 72,765,000 | 40,467,000 | 30,178,000 | 8,000 | 52,000 | |||
| Total liabilities: | 120,565,000 | 88,441,000 | 53,479,000 | 39,211,000 | 5,407,000 | 2,872,000 | |||
| Temporary equity, including noncontrolling interest | 1,723,000 | 1,723,000 | 1,723,000 | 1,723,000 | |||||
| Equity | |||||||||
| Equity, attributable to parent, including: | (104,793,000) | (61,964,000) | (33,917,000) | 893,000 | 22,470,000 | 43,872,000 | |||
| Preferred stock | 500,000 | 500,000 | 510,000 | 527,000 | |||||
| Common stock | 62,000 | 61,000 | 59,000 | 59,000 | 56,000 | 56,000 | |||
| Additional paid in capital | 296,217,000 | 291,847,000 | 275,081,000 | 271,001,000 | 261,883,000 | 259,673,000 | |||
| Accumulated deficit | (401,572,000) | (354,372,000) | (309,567,000) | (270,694,000) | (239,996,000) | (216,394,000) | |||
| Other undisclosed equity, attributable to parent | 527,000 | 537,000 | |||||||
| Other undisclosed equity | 1,723,000 | 1,723,000 | |||||||
| Total equity: | (104,793,000) | (61,964,000) | (33,917,000) | 893,000 | 24,193,000 | 45,595,000 | |||
| TOTAL LIABILITIES AND EQUITY: | 17,495,000 | 28,200,000 | 21,285,000 | 41,827,000 | 29,600,000 | 48,467,000 | |||
Income Statement (P&L) (USD)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Operating expenses | (42,433,000) | (38,072,000) | (38,352,000) | (30,179,000) | (23,444,000) | (13,438,000) | ||
| Operating loss: | (42,433,000) | (38,072,000) | (38,352,000) | (30,179,000) | (23,444,000) | (13,438,000) | ||
| Nonoperating income (expense) | (4,614,000) | (2,994,000) | (424,000) | (348,000) | (21,000) | 144,000 | ||
| Investment income, nonoperating | 926,000 | (202,000) | 609,000 | 141,000 | 66,000 | 231,000 | ||
| Interest and debt expense | (5,540,000) | (2,792,000) | (1,033,000) | (489,000) | (87,000) | (87,000) | ||
| Loss from continuing operations: | (52,587,000) | (43,858,000) | (39,809,000) | (31,016,000) | (23,552,000) | (13,381,000) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (31,016,000) | (23,552,000) | (13,381,000) | |
| Net loss: | (52,587,000) | (43,858,000) | (39,809,000) | (31,016,000) | (23,552,000) | (13,381,000) | ||
| Other undisclosed net income attributable to parent | 5,540,000 | 2,792,000 | 1,033,000 | 489,000 | 87,000 | 87,000 | ||
| Net loss attributable to parent: | (47,047,000) | (41,066,000) | (38,776,000) | (30,527,000) | (23,465,000) | (13,294,000) | ||
| Preferred stock dividends and other adjustments | (153,000) | (120,000) | (97,000) | (171,000) | (137,000) | (263,000) | ||
| Other undisclosed net loss available to common stockholders, basic | (3,619,000) | (6,622,000) | ||||||
| Net loss available to common stockholders, diluted: | (47,200,000) | (44,805,000) | (38,873,000) | (30,698,000) | (23,602,000) | (20,179,000) | ||
Comprehensive Income (USD)
| 12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (52,587,000) | (43,858,000) | (39,809,000) | (31,016,000) | (23,552,000) | (13,381,000) | ||
| Comprehensive loss, net of tax, attributable to parent: | (52,587,000) | (43,858,000) | (39,809,000) | (31,016,000) | (23,552,000) | (13,381,000) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.